The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use issued draft guidance on ICH Q14 in March 2022.
Labcorp Biopharmaceutical CMC Services has been at the forefront of implementing ICH Q14 guidelines and using risk-based approaches around QbD for CMC services.
This webinar focuses on non-invasive approaches to NAFLD/NASH drug development. During the webinar, speakers will provide updates on current and emerging NASH biomarkers, which are also anticipated to be important tools in clinical practice.
Key roles small RNA play in the field of biomarker discovery and current approaches to best quantify these targets and their expression using modern multi-step RT-qPCR methodology.
This roundtable focuses on approaches to accelerating your advanced therapy program by leveraging the combination of innovative technology and deep cross-industry insights from our cell and gene therapy scientists and operational leaders.
This roundtable focuses on approaches to accelerating your advanced therapy program by leveraging the combination of innovative technology and deep cross-industry insights from our cell and gene therapy scientists and operational leaders.
This roundtable focuses on approaches to accelerating your advanced therapy program by leveraging the combination of innovative technology and deep cross-industry insights from our cell and gene therapy scientists and operational leaders.
